The Syneos Health Podcast
The Syneos Health Podcast Series dissects some of the most complex issues biopharma leaders are facing today. Our clinical and commercial experts provide time-tested solutions, as well as perspectives on the news of the day. Hosted by Jeff Stewart, a long-time industry consultant who has advised biopharma leaders on licensing, mergers and acquisitions, pricing and market access, commercialization and go-to-market strategies, each episode explores the challenges and considerations involved with bringing biopharmaceuticals to the market.
Podcasting since 2017 • 147 episodes
The Syneos Health Podcast
Latest Episodes
Circulating Tumor DNA: Transforming Oncology Clinical Trials
Use of circulating tumor DNA (ctDNA) – small fragments of DNA that are released into the bloodstream by cancer cells – as a diagnostic tool represents a significant shift toward more precise, personalized cancer care, enhancing both trial effic...
•
20:01
Cashing in on the Currency of Information
Medical science liaisons—or MSLs—within pharmaceutical companies deal in a special currency: scientific exchange and real-world insights gathering. Only they can share certain types of information with a growing number of medical stakeholders. ...
•
34:22
Decoding Gen AI’s Potential to Drive More Effective Clinical Trials
AI is seemingly everywhere now in our lives, including healthcare and drug discovery and development. AI certainly has the potential to enable major advances than development of more effective and safe medical products. And in fact, GenAI has a...
•
31:32
Connecting the Global Dots on Carbon Footprint in Biopharma
The World Economic Forum projects that by 2050, climate change could cause 14 million additional deaths and $12 trillion in global healthcare costs. And this will exacerbate global health inequities with our most vulnerable populations, includi...
•
27:16
Can AI Help Get the Right Patients Into Alzheimer's Clinical Trials?
Alzheimer's disease is a challenging and devastating diagnosis that affects memory and cognitive skills, with no known way to predict, track, treat, or cure it effectively. In 2024, around 90 million people over the age of 65 will be living wit...
•
31:58